On December 13, 2018, Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) (Frankfurt: A2JMZC) announced that it had completed its previously announced acquisition of the Latin American Institute of Neurology and the Nervous System ("ILANS"). ILANS is one of the most respected, fastest growing and largest health service network providers in Colombia and Latin America.

Khiron, with core operations in Colombia, is positioned to be the dominant integrated medical cannabis company in Latin America. In May 2018, Khiron listed on the TSX Venture Exchange, becoming the first Colombian based medical cannabis company to trade on any exchange globally.

Gowling WLG advised Khiron with respect to this acquisition with a team that included Peter Simeon, Marek Lorenc and Josh Rosen.